Log in

Relevant bibliographies by topics / Prostate cancer immunotherapy / Dissertations / Theses

To see the other types of publications on this topic, follow the link: Prostate cancer immunotherapy.

Dissertations / Theses on the topic 'Prostate cancer immunotherapy'

Author: Grafiati

Published: 4 June 2021

Last updated: 14 February 2022

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 29 dissertations / theses for your research on the topic 'Prostate cancer immunotherapy.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse dissertations / theses on a wide variety of disciplines and organise your bibliography correctly.

1

Lundberg, Kajsa. "On immunotherapy against prostate cancer." Stockholm : Karolinska institutet, 2010. http://diss.kib.ki.se/2010/978-91-7409-805-1/.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Coletti, Roberta. "Mathematical modeling of prostate cancer immunotherapy." Doctoral thesis, Università degli studi di Trento, 2020. http://hdl.handle.net/11572/265805.

Full text

Abstract:

Immunotherapy, by enhancing the endogenous anti-tumor immune responses, is showing promising results for the treatment of numerous cancers refractory to conventional therapies. However, its effectiveness for advanced castration-resistant prostate cancer remains unsatisfactory and new therapeutic strategies need to be developed. To this end, mathematical modeling provides a quantitative framework for testing in silico the efficacy of new treatments and combination therapies, as well as understanding unknown biological mechanisms. In this dissertation we present two mathematical models of prosta

APA, Harvard, Vancouver, ISO, and other styles

3

Young, James Graham. "Gene & immunotherapy of prostate cancer." Thesis, University of Birmingham, 2002. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.289297.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Perry, Matthew James Alexander. "Suicide gene therapy and immunotherapy in prostate cancer." Thesis, St George's, University of London, 2002. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.271044.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Parkinson, Richard John. "The development of novel immunotherapy strategies for prostate cancer." Thesis, Nottingham Trent University, 2005. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.429271.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Dadvar, Ehsan. "Characterization of cancer/testis antigen MAGE-A11 for immunotherapy of prostate cancer." Master's thesis, Université Laval, 2014. http://hdl.handle.net/20.500.11794/26789.

Full text

Abstract:

Les antigènes testiculaires du cancer sont des cibles idéales pour l’immunothérapie du cancer car ce sont des protéines immunogéniques dont l’expression est restreinte aux cellules germinales et au cancer. Le but de cette étude est d’évaluer le potentiel de MAGE-A11, un antigène testiculaire du cancer, comme cible pour développer un vaccin contre le cancer de la prostate. Pour ce faire, l’anticorps monoclonal 5C4 qui a la capacité de reconnaître la présence de MAGE-A11 dans les tissus fixés et inclus en paraffine a été produit. De plus, l’expression de MAGE-A11 a été analysée sur plusieurs lig

APA, Harvard, Vancouver, ISO, and other styles

7

Dzojic, Helena. "Adenovirus-mediated CD40 Ligand Immunotherapy of Prostate and Bladder Cancer." Doctoral thesis, Uppsala : Acta Universitatis Upsaliensis : Univ.-bibl. [distributör], 2007. http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-7810.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Bird-Gordon, Kereen Suzetta. "Prostate Cancer Cells differentally express anti-inflmmatory and pro-inflammatory cytokines and chemokines: implications for prostate cancer immunotherapy." DigitalCommons@Robert W. Woodruff Library, Atlanta University Center, 2007. http://digitalcommons.auctr.edu/dissertations/12.

Full text

Abstract:

Anti-inflammatory specific cytokines and chemokines are elevated in many advanced tumors and correlate with poor prognosis. However, the differential expression of anti-inflammatory cytokines and chemokines in prostate cancer is not known. We investigated the hypotheses that androgen unresponsive DU145 and PC3 prostate cancer cells and androgen responsive LNCaP prostate cancer cells, differentially expressed selected anti-inflammatory and pro-inflammatory cytokines and chemokines and that, dendritic cells pulsed with prostate tumor antigens will induce mainly pro-inflammatory cytokines and che

APA, Harvard, Vancouver, ISO, and other styles

9

Spies, Elmar [Verfasser]. "Development and Characterization of a novel Immunotherapy against Prostate Cancer / Elmar Spies." Konstanz : Bibliothek der Universität Konstanz, 2012. http://d-nb.info/1028327595/34.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Viney, Richard Philip Charles. "Nitroreductase suicide gene and immunotherapy in locally relapsed, castrate resistant prostate cancer." Thesis, University of Birmingham, 2014. http://etheses.bham.ac.uk//id/eprint/5100/.

Full text

Abstract:

In this thesis we validate the efficacy of a new adenoviral construct in prostate cancer cell lines in preparation for a gene and immunotherapy clinical trial in prostate cancer. By demonstrating the constructs ability to infect prostate cancer cells and cause them to die with the introduction of the prodrug, CB1954 as well as releasing a biologically active cytokine, GMCSF we secured GTAC approval to proceed to a phase I/II clinical trial in patients with local relapse after treatment with curative intent for prostate cancer. A tertiary endpoint in the trial is evidence of immune responses re

APA, Harvard, Vancouver, ISO, and other styles

11

Graham, Jessica Beth. "Co-delivery of cationic polymers and adenovirus in immunotherapy of prostate cancer." Diss., University of Iowa, 2010. https://ir.uiowa.edu/etd/504.

Full text

Abstract:

Prostate cancer is the most common non-skin cancer in America, and the most commonly diagnosed cancer among males. When metastatic, the disease can ultimately be incurable. Consequently, alternative strategies to current treatments are sought, especially in the area of immunotherapy. Vaccine immunotherapy using a specific antigen, such as prostate specific antigen (PSA) seeks to stimulate both the innate and adaptive immune system to destroy tumor cells in the body. PSA is an ideal target antigen given that it has a narrow distribution in tissues and is expressed in virtually all prostate canc

APA, Harvard, Vancouver, ISO, and other styles

12

Nada, Mohanad Hameed. "Adoptive cancer immunotherapy with human Vγ2vδ2 T cells". Diss., University of Iowa, 2016. https://ir.uiowa.edu/etd/2247.

Full text

Abstract:

Human γδ T cells expressing Vγ2Vδ2 TCRs monitor foreign- and self-prenyl pyrophosphate metabolites in isoprenoid biosynthesis to mediate immunity to microbes and tumors. Vγ2Vδ2 cells have been used for adoptive cancer immunotherapy with some partial and complete remissions. Most trials have used continuous zoledronate exposure to expand Vγ2Vδ2 cells. Zoledronate inhibits farnesyl pyrophosphate synthase causing isopentenyl pyrophosphate to accumulate that then stimulates Vγ2Vδ2 cells. Because zoledronate exposure is toxic, we hypothesized that a short period of exposure would reduce T cell toxi

APA, Harvard, Vancouver, ISO, and other styles

13

Forsberg, Ole. "Generation of Therapeutic T Cells for Prostate Cancer." Doctoral thesis, Uppsala : Acta Universitatis Upsaliensis : Univ.-bibl. [distributör], 2009. http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-100506.

Full text

APA, Harvard, Vancouver, ISO, and other styles

14

Roos, Anna-Karin. "Delivery of DNA vaccines against cancer /." Stockholm, 2006. http://diss.kib.ki.se/2006/91-7140-895-9/.

Full text

APA, Harvard, Vancouver, ISO, and other styles

15

Aarab-Terrisse, Safae. "Impact de l'axe microbiome-thymus sur l'efficacité de la déprivation androgénique et sur le renforcement de l’immuno-surveillance dans le cancer de la prostate Immunodynamics of Explanted Human Tumors for Precision and Personalized Immuno-Oncology Gut Bacteria Composition Drives Primary Resistance to Cancer Immunotherapy in Renal Cell Carcinoma Patients." Thesis, université Paris-Saclay, 2020. http://www.theses.fr/2020UPASL025.

Full text

Abstract:

La déprivation androgénique est la pierre angulaire du traitement du cancer de la prostate (CaP), mais la plupart des patients deviendront réfractaires à la castration (CRPC). En outre, les immunothérapies par inhibiteurs de points de contrôle immunitaire ne sont pour l’instant pas un standard dans la prise en charge de ce cancer en raison de son environnement immunosuppresseur. Notre hypothèse est que pour accroître la sensibilité des patients aux traitements immuno-modulateurs (déprivation androgénique, inhibiteurs des points de contrôle immunitaire et autres), il faudrait restaurer l’enviro

APA, Harvard, Vancouver, ISO, and other styles

16

John, Robert Justin. "Studies into the generation and cryopreservation of dendritic cells and their application in prostate and renal cancer immunotherapy." Thesis, St George's, University of London, 2006. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.428982.

Full text

APA, Harvard, Vancouver, ISO, and other styles

17

Sullivan, Camille. "Epithelial and Macrophage RON Receptor Signaling Regulates the Antitumor Immune Response in Prostate Cancer." University of Cincinnati / OhioLINK, 2020. http://rave.ohiolink.edu/etdc/view?acc_num=ucin159524743258716.

Full text

APA, Harvard, Vancouver, ISO, and other styles

18

Pournaras, Christos Verfasser], Jürgen E. [Akademischer Betreuer] [Gschwend, and Margitta [Akademischer Betreuer] Retz. "CpG-DNA – a potential adjuvant in prostate cancer immunotherapy / Christos Pournaras. Gutachter: Jürgen E. Gschwend ; Margitta Retz. Betreuer: Jürgen E. Gschwend." München : Universitätsbibliothek der TU München, 2014. http://d-nb.info/1050817516/34.

Full text

APA, Harvard, Vancouver, ISO, and other styles

19

Pournaras, Christos [Verfasser], Jürgen E. [Akademischer Betreuer] Gschwend, and Margitta [Akademischer Betreuer] Retz. "CpG-DNA – a potential adjuvant in prostate cancer immunotherapy / Christos Pournaras. Gutachter: Jürgen E. Gschwend ; Margitta Retz. Betreuer: Jürgen E. Gschwend." München : Universitätsbibliothek der TU München, 2014. http://nbn-resolving.de/urn:nbn:de:bvb:91-diss-20140225-959273-0-8.

Full text

APA, Harvard, Vancouver, ISO, and other styles

20

Lebdai, Souhil. "Potentialisation de la photothérapie dynamique à visée vasculaire par une modulation des cellules myéloïdes par le récepteur CSF-1R dans un modèle préclinique de cancer de la prostate Les traitements focaux : une alternative dans la prise en charge du cancer de la prostate de bas risque ? Potentiating vascular-targeted photodynamic therapy through CSF-1R modulation of myeloid cells in a preclinical model of prostate cancer." Thesis, Sorbonne université, 2019. http://www.theses.fr/2019SORUS521.

Full text

Abstract:

La photothérapie dynamique à visée vasculaire utilisant le WST11 (VTP) induit la destruction rapide des tissus ciblés et constitue un traitement prometteur pour le cancer de la prostate. Cependant, la réponse immunitaire qui en résulte, qui peut jouer un rôle important dans la potentialisation ou l’atténuation des effets de la VTP, n’a toujours pas été comprise. Les cellules myéloïdes, telles que les MDSC et les macrophages, sont souvent présentes dans les tumeurs et sont largement associées à l'angiogenèse, au remodelage tissulaire et à l'immunosuppression. On sait également que ces cellules

APA, Harvard, Vancouver, ISO, and other styles

21

Carlsson, Björn. "Adoptive T Cell Therapy of Viral Infection and Cancer : Ex vivo Expansion of Cytomegalovirus- and Prostate Antigen-specific T Cells." Doctoral thesis, Uppsala University, Clinical Immunology, 2005. http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-4821.

Full text

Abstract:

<p>The main focus of my thesis has been to develop protocols for generating antigen-specific cytotoxic T lymphocytes (CTLs) and T helper cells (T<sub>H</sub>) for adoptive transfer to treat cytomegalovirus (CMV) disease and prostate cancer. CMV viremia is a severe complication in immunocompromised stem cell transplanted patients. Prostate cancer is a leading cause of death for men in Western countries. Although different in nature, CMV-infected cells and prostate cancer cells can both be eliminated through specific activation of the adaptive immune system. </p><p>To generate CMV pp65-specific

APA, Harvard, Vancouver, ISO, and other styles

22

Veuillen, Caroline. "Caractérisation des mécanismes d'échappement tumoral à la lyse NK dans la LLC-B et le cancer de la prostate." Thesis, Aix-Marseille 2, 2011. http://www.theses.fr/2011AIX20708.

Full text

Abstract:

De nombreuses données expérimentales et cliniques ont montré l'importance des cellules Natural Killer (NK) dans l'immunosurveillance antitumorale. Les stratégies thérapeutiques basées sur les cellules NK pourraient donc être une alternative de choix dans le traitement de certains types de cancers. Nous avons focalisé notre étude sur deux types de cancer incurables malgré les récents progrès thérapeutiques : la leucémie lymphoïde chronique B (LLC-B) et le cancer de la prostate. Le but de notre étude est une meilleure compréhension des mécanismes mis en place par les cellules B leucémiques et le

APA, Harvard, Vancouver, ISO, and other styles

23

Petitprez, Florent. "Integrated analysis and clinical impact of immune and stromal microenvironments in solid tumors Quantitative analyses of the tumor microenvironment composition and orientation in the era of precision medicine Transcriptomic analysis of the tumor microenvironment to guide prognosis and immunotherapies Tumor microenvironment quantification tool draws a comprehensive map of the tumor microenvironment of non-hematologic human cancers The mMCP-counter method to estimate abundance of tissue-infiltrating immune and stromal cell populations using gene expression in murine samples Immune sub-classes in sarcoma predict survival and immunotherapy response Intra-tumoral tertiary lymphoid structures are associated with a low risk of hepatocellular carcinoma early recurrence Association of IL-36γ with tertiary lymphoid structures and inflammatory immune infiltrates in human colorectal cancer Immune-based identification of cancer patients at high risk of progression Tumor-infiltrating and peripheral blood T-cell immunophenotypes predict early relapse in localized clear cell renal cell carcinoma PD-L1 expression and CD8+ T-cell infiltrate are associated with clinical progression in patients with node-positive prostate cancer Intratumoral classical complement pathway activation promotes cancer progression". Thesis, Sorbonne Paris Cité, 2018. http://www.theses.fr/2018USPCB104.

Full text

Abstract:

Les tumeurs sont composées de cellules malignes et d'une grande variété de cellules non-tumorales, en particulier des cellules immunitaires qui forment le micro-environnement tumoral (MET). Il a été démontré que la composition du MET était associée au devenir clinique des patients, en termes de survie et de réponses thérapeutiques. Avec le développement récent des immunothérapies qui ciblent des éléments spécifiques du MET, l'immunité anti-tumorale a soulevé un intérêt majeur. Plusieurs méthodologies ont été mises au point afin d'étudier la composition du MET, avec une précision toujours plus

APA, Harvard, Vancouver, ISO, and other styles

24

Mossoba, Miriam Esmat. "Development of Immunotherapy Against Prostate Cancer Using Lentivirally-transduced Dendritic Cells Expressing Murine erbB2 as a Model Tumor-associated Antigen." Thesis, 2008. http://hdl.handle.net/1807/16783.

Full text

Abstract:

Prostate cancer is a leading cause of cancer deaths in North American men. Current treatments are often not curative, particularly in cases of advanced metastatic disease. Immunotherapy is a promising approach to treating cancer as it harnesses the immune system’s ability to mount potent responses against tumor-associated antigens (TAAs). Dendritic cells (DCs) play a central role in mediating antigen-specific immunity and have been recently used with some success in clinical trials. The difficulties associated with obtaining sufficient quantities of DCs from cancer patients provided the ration

APA, Harvard, Vancouver, ISO, and other styles

25

Joshi, Jay. "Understanding the mechanism of 177Lu- PSMA617 radioligand therapy and evaluating its potential role in the treatment of metastatic castrate resistant prostate cancer (mCRPC)." Thesis, 2020. http://hdl.handle.net/1828/12479.

Full text

Abstract:

Prostate cancer is the most common cancer in men and the third leading cause of cancer-related deaths in Canadian men. Despite hormone and radiation therapies, most patients progress to late-stage metastatic castrate-resistant prostate cancer (mCRPC). 177Lu-PSMA617 radioligand therapy (rLT) is a radioactive biochemical substance that targets the human prostate-specific membrane antigen (hPSMA). This rLT has been used in compassionate trials in mCRPC patients and has been demonstrated significant clinical efficacy. However, recent findings suggest that this efficacy is short-lived, and most pat

APA, Harvard, Vancouver, ISO, and other styles

26

Groth, Ariane [Verfasser]. "Gene-immunotherapy with TRAIL and bispecific antibody EpCAMxCD3 for the selective induction of apoptosis in advanced pancreatic and prostate cancer / presented by Ariane Groth." 2010. http://d-nb.info/100422334X/34.

Full text

APA, Harvard, Vancouver, ISO, and other styles

27

Vávrová, Kateřina. "Adoptivní transfer tumor-specifických lymfocytů v imunoterapii nádorových onemocnění." Doctoral thesis, 2020. http://www.nusl.cz/ntk/nusl-435278.

Full text

Abstract:

Prostate cancer is the second leading cause of cancer death in men in Europe and the US. In the context of previous preclinical experiments and clinical studies there are certain assumptions predicating successful application of immunotherapy in the treatment of patients with prostate cancer. Promising results have been achieved by a combination of different treatment modalities which provide a synergistic antitumor effect. One of these combinatorial options is the use of antitumor vaccines and adoptive T cell transfer. The topic of this thesis is to provide a fresh insight into the past and c

APA, Harvard, Vancouver, ISO, and other styles

28

Baptista, Ana Catarina Figueiredo. "Vacinas anti-tumorais baseadas em células dendríticas no cancro da próstata." Master's thesis, 2018. http://hdl.handle.net/10316/84593.

Full text

Abstract:

Relatório de Estágio do Mestrado Integrado em Ciências Farmacêuticas apresentado à Faculdade de Farmácia<br>O cancro da próstata é uma das neoplasias sólidas mais comuns e trata-se de um problema do mundo moderno, tendo uma maior incidência em países mais desenvolvidos e em homens de idade mais avançada. O diagnóstico precoce do tumor, com a deteção da doença numa fase inicial, está associado a uma maior taxa de sucesso do tratamento e, consequentemente, a um melhor prognóstico. Os esquemas terapêuticos são adaptados a cada doente de acordo com o estádio da doença e as opções terapêuticas disp

APA, Harvard, Vancouver, ISO, and other styles

29

G, Leclerc Bruno. "Valeur pronostique de CD73 et des lymphocytes T CD8 et optimisation de la vaccination de type GVAX dans le cancer de la prostate." Thèse, 2015. http://hdl.handle.net/1866/15907.

Full text

Abstract:

CD73 est un ecto-enzyme qui a été associé à la suppression de l'immunité anti-tumorale. Ses valeurs pronostiques et thérapeutiques ont été mises de l'avant dans plusieurs types de cancer. La première hypothèse du projet est que l'expression de CD73 dans la tumeur prédit le pronostic des patients atteints du cancer de la prostate. L'expression de CD73 a été étudiée par immunofluorescence dans des échantillons de tumeur. Puis, des analyses univariées et multivariées ont été conduites pour déterminer si l'expression de CD73 permet de prédire la récidive biochimique des patients. Nous avons déterm

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!